|
Jul 29
|
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
|
|
Jul 28
|
Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN)
|
|
Jul 27
|
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
|
|
Jul 26
|
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
|
|
Jul 25
|
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
|
Jul 25
|
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
|
|
Jul 25
|
Regeneron Pharmaceuticals Earnings Preview: What to Expect
|
|
Jul 24
|
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
|
|
Jul 24
|
Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip
|
|
Jul 24
|
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
|
|
Jul 24
|
3 Low-Volatility Stocks We Steer Clear Of
|
|
Jul 23
|
TOP SCIENCE TEACHERS ANNOUNCED FOR 12TH ANNUAL REGENERON STEM TEACHING FELLOWSHIP
|
|
Jul 23
|
Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances
|
|
Jul 21
|
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
|
|
Jul 18
|
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
|
|
Jul 15
|
Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.
|
|
Jul 15
|
Health Canada extends Evkeeza approval for children with HoFH
|
|
Jul 15
|
1 Healthcare Stock on Our Buy List and 2 to Brush Off
|
|
Jul 14
|
Ascites Market Analysis and Forecasts Report 2025-2035 | Market Surges Amid Rising Liver Disease and Cancer Prevalence
|
|
Jul 14
|
Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments
|